Phase IINeuropeptide
Compound 61687
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061687
Risk Class
MODERATE
Last Audit
Jun 12, 2108
Research Abstract
Neuropeptide candidate engineered for endocrine support initiatives with automated dossier coverage.
Compound 61687 is a neuropeptide asset inside neuropeptide innovation track initiatives, optimized for endocrine support and performance longevity.
The dossier currently sits in phase ii with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061687 with updates logged 2108-06-12.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Endocrine supportPerformance longevity
Nomenclature
CX-61687Neuropeptide Program 61687
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061687
- [2] Operations Pulse • Neuropeptide innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61687